[
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View",
    "summary": "EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.",
    "url": "https://finnhub.io/api/news?id=613817e305baa2a9d7db7836b7c82e8e772fc26aa093f55816637f7c2bbbea17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732305600,
      "headline": "Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View",
      "id": 131573734,
      "image": "https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.",
      "url": "https://finnhub.io/api/news?id=613817e305baa2a9d7db7836b7c82e8e772fc26aa093f55816637f7c2bbbea17"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio heart drug approved by FDA, setting up battle with Pfizer",
    "summary": "The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.",
    "url": "https://finnhub.io/api/news?id=03263f93b72f1c106b21b74517ceb70c1384b0a42907bf39090e5d7a39549850",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732302979,
      "headline": "BridgeBio heart drug approved by FDA, setting up battle with Pfizer",
      "id": 131576708,
      "image": "https://imgproxy.divecdn.com/RD21L2-dmmvv-pSMpGSONH98yYJ7lfq6SfY19YwpEps/g:nowe:0:100/c:8192:4628/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY2Nzk1NzQ2LmpwZw==.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.",
      "url": "https://finnhub.io/api/news?id=03263f93b72f1c106b21b74517ceb70c1384b0a42907bf39090e5d7a39549850"
    }
  },
  {
    "ts": null,
    "headline": "Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics",
    "summary": "NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.",
    "url": "https://finnhub.io/api/news?id=2c98a9f8b0048d418f53a466691ef2406a52a00b4e5bf6dcc5338716110751f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732300620,
      "headline": "Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics",
      "id": 131570895,
      "image": "https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.",
      "url": "https://finnhub.io/api/news?id=2c98a9f8b0048d418f53a466691ef2406a52a00b4e5bf6dcc5338716110751f2"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts Bayer's Application for Label Expansion of Nubeqa",
    "summary": "Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.",
    "url": "https://finnhub.io/api/news?id=5fea78e42c86b8772fc5433b57b5370451dead4d0ba82da249139041d638cc65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732300560,
      "headline": "FDA Accepts Bayer's Application for Label Expansion of Nubeqa",
      "id": 131570445,
      "image": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.",
      "url": "https://finnhub.io/api/news?id=5fea78e42c86b8772fc5433b57b5370451dead4d0ba82da249139041d638cc65"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=777026265d38c75c60c08b476b2b81e3d6ccda1e91241a589c473b949e81778e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293600,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 131601000,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=777026265d38c75c60c08b476b2b81e3d6ccda1e91241a589c473b949e81778e"
    }
  },
  {
    "ts": null,
    "headline": "Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug",
    "summary": "REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.",
    "url": "https://finnhub.io/api/news?id=6c41a449f2369d42bdedc488a2903d2884341ed708e807648e3875ccda97173b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732292580,
      "headline": "Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug",
      "id": 131568433,
      "image": "https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.",
      "url": "https://finnhub.io/api/news?id=6c41a449f2369d42bdedc488a2903d2884341ed708e807648e3875ccda97173b"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?",
    "summary": "RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?",
    "url": "https://finnhub.io/api/news?id=3a22a90214c3c17f3eab9e414ce55dd3828e9c220a3562cd7032c994b9f3a5e4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732292245,
      "headline": "RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?",
      "id": 131598519,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?",
      "url": "https://finnhub.io/api/news?id=3a22a90214c3c17f3eab9e414ce55dd3828e9c220a3562cd7032c994b9f3a5e4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
    "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
    "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732288243,
      "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
      "id": 131571049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153992734/image_2153992734.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
      "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Jefferies London Healthcare Conference Transcript",
    "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Pfizer Inc at Jefferies London Healthcare Conference EVENT...",
    "url": "https://finnhub.io/api/news?id=c88d8a802016333d370abdfa5374244702c7b8ea77a5b3f9b4755c68c1a1432c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732286286,
      "headline": "Pfizer : Jefferies London Healthcare Conference Transcript",
      "id": 131570183,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Pfizer Inc at Jefferies London Healthcare Conference EVENT...",
      "url": "https://finnhub.io/api/news?id=c88d8a802016333d370abdfa5374244702c7b8ea77a5b3f9b4755c68c1a1432c"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia's Big Buildup, Then A Shrug",
    "summary": "Nvidia earnings - big buildup, then a shrug. How long can Bitcoin's run can last?",
    "url": "https://finnhub.io/api/news?id=c704dcb89297fafca5d9d2b12fda2a8fd625f16701568903a3fafa65322901da",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732279800,
      "headline": "Nvidia's Big Buildup, Then A Shrug",
      "id": 131568219,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1006384150/image_1006384150.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Nvidia earnings - big buildup, then a shrug. How long can Bitcoin's run can last?",
      "url": "https://finnhub.io/api/news?id=c704dcb89297fafca5d9d2b12fda2a8fd625f16701568903a3fafa65322901da"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Jefferies London Healthcare Conference (Transcript)",
    "summary": "Pfizer Inc. (NYSE:PFE) Jefferies London Healthcare Conference November 20, 2024 4:00 AM ETCompany ParticipantsDave Denton - CFOAndrew Baum - Chief Strategy...",
    "url": "https://finnhub.io/api/news?id=3a2f8e8d49f9cb23076977eae29220c917a17d9a7b7a6a4df75480c6c893cca4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732278621,
      "headline": "Pfizer Inc. (PFE) Jefferies London Healthcare Conference (Transcript)",
      "id": 131567988,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. (NYSE:PFE) Jefferies London Healthcare Conference November 20, 2024 4:00 AM ETCompany ParticipantsDave Denton - CFOAndrew Baum - Chief Strategy...",
      "url": "https://finnhub.io/api/news?id=3a2f8e8d49f9cb23076977eae29220c917a17d9a7b7a6a4df75480c6c893cca4"
    }
  },
  {
    "ts": null,
    "headline": "Zai Lab and Pfizer to commercialise XACDURO in China",
    "summary": "Pfizer's affiliated companies have exclusive rights to undertake commercialisation activities for the drug.",
    "url": "https://finnhub.io/api/news?id=87f89fc54a92a6ac1e52b0ac14625ae09ae5ed36527c8c652fcef233b1093a7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732275391,
      "headline": "Zai Lab and Pfizer to commercialise XACDURO in China",
      "id": 131562023,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/Pharma-2-Zai-Shutterstock_2348634997.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's affiliated companies have exclusive rights to undertake commercialisation activities for the drug.",
      "url": "https://finnhub.io/api/news?id=87f89fc54a92a6ac1e52b0ac14625ae09ae5ed36527c8c652fcef233b1093a7a"
    }
  },
  {
    "ts": null,
    "headline": "Tel Aviv University: Nasal Spray Revolutionizes COVID Protection",
    "summary": "A breakthrough in vaccine development: Prof. Ronit Satchi-Fainaro's lab at TAU's Faculty of Medical and Health Sciences collaborated with Professor Helena Florindo's lab at the University of Lisbon to...",
    "url": "https://finnhub.io/api/news?id=e680b1bcc0db5895db0b884122a696091f46df79de6b9941f82100e5b38f4200",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732252385,
      "headline": "Tel Aviv University: Nasal Spray Revolutionizes COVID Protection",
      "id": 131559523,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "A breakthrough in vaccine development: Prof. Ronit Satchi-Fainaro's lab at TAU's Faculty of Medical and Health Sciences collaborated with Professor Helena Florindo's lab at the University of Lisbon to...",
      "url": "https://finnhub.io/api/news?id=e680b1bcc0db5895db0b884122a696091f46df79de6b9941f82100e5b38f4200"
    }
  },
  {
    "ts": null,
    "headline": "The Irish Government Is Unbelievably Rich. It’s Largely Thanks to Uncle Sam.",
    "summary": "EUROPE NEWS  DUBLIN—The Irish government is rolling in clover like never before. The country currently has so much money it pumps cash into not one but two sovereign-wealth funds. It is so flush that the budget watchdog doesn’t warn about not having enough money but rather that the government is spending so much that it could overheat the economy.",
    "url": "https://finnhub.io/api/news?id=8d6284f7d624d2a1436961a5c5e7b45571ff4561ba3abbe47c257f4ee9a22197",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732251660,
      "headline": "The Irish Government Is Unbelievably Rich. It’s Largely Thanks to Uncle Sam.",
      "id": 131556895,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "EUROPE NEWS  DUBLIN—The Irish government is rolling in clover like never before. The country currently has so much money it pumps cash into not one but two sovereign-wealth funds. It is so flush that the budget watchdog doesn’t warn about not having enough money but rather that the government is spending so much that it could overheat the economy.",
      "url": "https://finnhub.io/api/news?id=8d6284f7d624d2a1436961a5c5e7b45571ff4561ba3abbe47c257f4ee9a22197"
    }
  }
]